Pfizer (PFE): Is This Healthcare Giant’s Valuation Now Too Low to Ignore?

Pfizer (PFE) has been moving quietly but steadily in the background, and that is catching the eye of many investors who are wondering whether it is time to take another look at this blue-chip name. No single event has triggered the recent attention, but the stock’s trajectory over the past year stands out and is sparking conversations about its valuation and place in a shifting healthcare landscape.

Over the past year, Pfizer’s share price has drifted lower despite ongoing developments in its pipeline. While the biotech sector has seen pockets of strong growth, Pfizer’s momentum has faded, reflected in a loss of 12% for the year and down nearly 10% year-to-date. Recent headlines have centered on product launches and regulatory updates, but these have yet to translate into lasting gains for shareholders.

After these declines and with expectations shifting, is Pfizer now trading at a bargain, or has the market already factored in all the uncertainty and risk ahead?

Most Popular Narrative: 21.5% Undervalued

The prevailing narrative suggests Pfizer’s stock is undervalued by a notable margin, hinting at potential upside from current levels.

I think that Pfizer has a strong pipeline. The acquisition of Seagen added many new oncology products that will continue to grow by 14%, partially offsetting the decline on sales of the covid-19 vaccines. This should keep revenue flat, possibly growing in low to mid single digits in an optimistic scenario.

Curious how a pharma giant is plotting its comeback? Hints of accelerating product launches, giant acquisition moves, and a focus on operational muscle are at play. The details behind the valuation case include bold assumptions on growth and margins. What aggressive financial vision underlies this bullish stance?

Result: Fair Value of $30.62 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent high debt and the potential for a dividend cut remain key risks. These factors could challenge Pfizer’s recovery and dampen investor enthusiasm.

Find out about the key risks to this Pfizer narrative.

Another View: SWS DCF Model

While many investors are focusing on Pfizer’s strong multiples story, our SWS DCF model also indicates the stock is trading well below its estimated fair value. Could both methods be pointing to a genuine opportunity, or is there a hidden risk that the market is spotting?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pfizer for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Pfizer Narrative

Not convinced by these takes, or want to dig deeper into the numbers yourself? You can easily craft your own perspective in just a few minutes. Do it your way

A great starting point for your Pfizer research is our analysis highlighting 5 key rewards and 3 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Stay ahead of the curve by targeting proven opportunities before others catch on. You can spot your next potential winner with these handpicked investment ideas, crafted for those who want more than the ordinary.

• Accelerate your portfolio with companies driving medical breakthroughs and powerful software by checking out our healthcare innovators powered by artificial intelligence via healthcare AI stocks.
• Capture potential high yields and secure your dividend income with businesses showing consistently strong payouts. See what’s available with dividend stocks with yields > 3%.
• Harness the power of undervalued gems that offer attractive entry points and future upside. Start your search with undervalued stocks based on cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com